PubMed HealthSearch

PubMed · 6529601

Longitudinal methods for evaluating therapy.

Abstract

Longitudinal studies of therapy are unparalleled in their ability to ensure scientifically cogent results by clearly separating cause (therapy) from effect (therapeutic outcome), by allowing incorporation of duration of follow-up into the assessment of comparative outcomes, and by permitting the use of safeguards against non-concurrent therapies, unequal prognostic susceptibilities, unequal therapeutic performance, and unequal detection of outcomes. The price of these advantages includes the reduced ability of longitudinal studies to evaluate therapies whose outcomes occur rarely or with long latencies, as well as the specific logistic, ethical, and design problems that limit the ability of clinical trials to answer many of the therapeutic questions which are important to clinical practice. The implications of these limitations are that longitudinal evaluations may not be suitable for addressing many therapeutic issues--particularly those involving preventive therapies--and that even when longitudinal studies are suitable, randomized trials may not be logistically feasible or ethically permissible to answer every clinically important question. One of the important challenges for research in this area is to develop alternative methods for assessing therapeutic effectiveness.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J D Clemens, R I Horwitz. 1984. Longitudinal methods for evaluating therapy.. https://pubmed.ncbi.nlm.nih.gov/6529601/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Gene therapy for cancer: what have we done and where are we going?

Gene-based therapies for cancer in clinical trials include strategies that involve augmentation of immunotherapeutic and chemotherapeutic approaches. These strategies include ex vivo and in vivo cytokine gene transfer, drug sensitization with genes for prodrug delivery, and the use of drug-resistance genes for bone marrow protection from high-dose chemotherapy. Inactivation of oncogene expression and gene replacement for tumor suppressor genes are among the strategies for targeting the underlying genetic lesions in the cancer cell. A review of clinical trial results to date, primarily in patients with very advanced cancers refractory to conventional treatments, indicates that these treatments can mediate tumor regression with acceptably low toxicity. Vector development remains a critical area for future research. Important areas for future research include modifying viral vectors to reduce toxicity and immunogenicity, increasing the transduction efficiency of nonviral vectors, enhancing vector targeting and specificity, regulating gene expression, and identifying synergies between gene-based agents and other cancer therapeutics.

Clinical Trials as Topic